News Details - novonordisk.com
Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
Jan 2, 2025 · When evaluating under the trial product estimand, findings showed CagriSema-treated patients achieved a superior weight loss of 22.7% compared with 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo after 68 weeks.
CagriSema Demonstrates Superior Weight Loss in Adults with …
Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
Novo Nordisk will test CagriSema's long-term efficacy in late …
18 hours ago · Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy, according to a www.clinicaltrials.gov entry.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk successfully completes phase 2 trial with
Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual...
Novo Nordisk’s CagriSema demonstrates superior weight loss …
Dec 22, 2024 · Conducted as part of the company’s phase 3 clinical programme, this trial highlights the efficacy of CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, in promoting substantial weight loss.
New Weight Loss Drug CagriSema Shows Impressive Results in
Jul 17, 2023 · Clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes and weight management treatment. Developed by Novo Nordisk, CagriSema is a combination medication of cagrilintide and the GLP-1 receptor agonist semaglutide.